Can-Fite Biopharma Accounts Payable

As of the most recent data (December 2025), CANF shows a accounts payable of $1.2M. That compares with $620K in the prior-year period — up 87.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CANF's accounts payable is now $1.2M (was $620K) — a 87.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Can-Fite Biopharma is outperforming or lagging.

Tracking CANF's accounts payable over time shows whether Can-Fite Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $1.2M That compares with $620K in the prior-year period — up 87.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Can-Fite Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $1.2M) with ownership activity and broader fundamentals.

Can-Fite Biopharma's accounts payable is $1.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.